These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21793633)

  • 1. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
    Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
    Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients.
    Brandhorst G; Petrova DT; Weigand S; Eberle C; von Ahsen N; Schmitz J; Schultze FC; Raddatz D; Karaus M; Oellerich M; Walson PD
    World J Gastroenterol; 2015 Mar; 21(11):3325-9. PubMed ID: 25805940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
    Hvas CL; Kelsen J; Agnholt J; Dige A; Christensen LA; Dahlerup JF
    Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.
    Blache C; Lequerré T; Roucheux A; Beutheu S; Dedreux I; Jacquot S; Le Loët X; Boyer O; Vittecoq O
    Rheumatology (Oxford); 2011 Oct; 50(10):1814-22. PubMed ID: 21791546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The subpopulation CD4(+); CD25(+); Foxp3(+);/CD127(low/-); regulatory T cells in peripheral blood of HIV-infected patients correlated with disease progression].
    Chen YL; Chen XR; Qin LX; Yang YF; Tang YM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1188-91. PubMed ID: 23127412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
    Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
    Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
    Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
    Kikuchi J; Hashizume M; Kaneko Y; Yoshimoto K; Nishina N; Takeuchi T
    Arthritis Res Ther; 2015 Jan; 17(1):10. PubMed ID: 25604867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease.
    Clerici M; Cassinotti A; Onida F; Trabattoni D; Annaloro C; Della Volpe A; Rainone V; Lissoni F; Duca P; Sampietro G; Fociani P; Vago G; Foschi D; Ardizzone S; Deliliers GL; Porro GB
    Dig Liver Dis; 2011 Dec; 43(12):946-52. PubMed ID: 21907652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease.
    Dige A; Støy S; Rasmussen TK; Kelsen J; Hvas CL; Sandahl TD; Dahlerup JF; Deleuran B; Agnholt J
    J Crohns Colitis; 2013 Apr; 7(3):248-55. PubMed ID: 22784949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB; Sagynbaeva VÉ
    Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
    Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
    Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.